课题基金 / 基金详情

Innovation and Knowledge Centre Regenerative Therapies and Devices Tranche 1 IKC RTD

Innovation and Knowledge Centre Regenerative Therapies and Devices Tranche 1 IKC RTD
创新和知识中心再生疗法和设备第 1 期 IKC RTD
批准号:
EP/I019103/1
负责人:
John Fisher
金额:
$351.82万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2011
资助国家:
英国
项目状态:
已结题
起止时间:
2011 至 --

项目摘要

项目成果

John Fisher的其他基金

相似基金

相关文献

中文摘要
翻译
再生疗法和设备创新和知识中心将提供一个可持续的平台,以解决再生疗法和设备新技术的创造问题。在成本限制日益增加的复杂全球市场中,它将以更高的可靠性促进它们的加速采用。促进身体组织再生的疗法和设备提供了彻底改变医疗保健的潜力,并成为经济增长的催化剂,在医疗保健技术领域创造了一个新的商业领域。IKC RTD将通过开发新的创新基础设施和实践,以大学及其合作伙伴(行业,NHS和中介/用户)的文化和研究景观为基础,提供主要的临床,健康和行业成果。在运作的第一年,IKC有:招募并建立一个核心创新团队来管理和发展IKC.2的活动。建立学术供应链,拥有160名研究人员的新中心。获得5000万新研究收入,资助120多个研究项目。确立了创新的新战略框架。建立了一个创新管道,有阶段门和进步标准。通过定义独特的功能来定义和开发IP组合。建立了63个协同创新项目。与26家不同的公司合作创新项目。与80多家公司建立了更广泛的网络。促成了九种新产品上市。定义了IKC rtd的可持续性模型。通过政治访问和媒体对研究和创新的广泛报道,获得了重大的国家和全球认可。
英文摘要
The Innovation and Knowledge Centre in Regenerative Therapies and Devices will provide a sustainable platform to address the creation of new technologies in Regenerative Therapies and Devices. It will promote their accelerated adoption, with increased reliability, within a complex global marketplace with increasing cost constraints. Therapies and devices which facilitate the regeneration of body tissues offer the potential to revolutionise healthcare and be a catalyst for economic growth, creating a new business sector within healthcare technology. The IKC RTD will build upon the culture and research landscape of the University and its partners (industry, NHS and intermediaries/users) through the development of new innovation infrastructure and practices which deliver major clinical, health and industry outcomes.In the first year of operation the IKC has:1. Recruited and established a core innovation team to manage and grow the activities of the IKC.2. Established academic supply chain, new centre with 160 researchers.3. Won 50m new research income, funding over 120 research projects.4. Defined a new strategic framework for innovation.5. Established an innovation pipeline with stage gates and criteria for progression.6. Defined and developed the IP portfolio through definition of the unique capabilities.7. Established a pipeline of 63 collaborative innovation projects.8. Engaged with 26 different companies in collaborative innovation projects.9. Established a wider network of 80 plus companies.10. Contributed to nine new products that have reached the market.11. Defined a model for sustainability of IKC RTD.12. Received significant national and global recognition through political visits and extensive media coverage for research and innovation.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
Novel Fully Resorbable Calcium Phosphate Microspheres for Biomedical Application
用于生物医学应用的新型完全可吸收磷酸钙微球
DOI: --
发表时间: 2016
期刊:
影响因子: --
作者: [Ahmed, I]
通讯作者: Ahmed, I
DOI: 10.1016/j.jmbbm.2017.11.022
发表时间: 2018-03
期刊: Journal of the mechanical behavior of biomedical materials
影响因子: 3.9
作者: [Abdelgaied A, Fisher J, Jennings LM]
通讯作者: Jennings LM
DOI: 10.1177/0954411917696519
发表时间: 2017-07
期刊: Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine
影响因子: --
作者: [Abdelgaied A, Fisher J, Jennings LM]
通讯作者: Jennings LM
DOI: 10.1177/0954411913513251
发表时间: 2014-01
期刊: Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine
影响因子: --
作者: [Abdelgaied A, Brockett CL, Liu F, Jennings LM, Jin Z, Fisher J]
通讯作者: Fisher J
8
    NSF/FDA SIR: 3D Human Stem Cell Cardiac Model for Cardiac Electrophysiology Medical Device Safety Assessment
    Collaborative Research: 4D Bioprinting of Near-infrared Light Responsive Smart Constructs for Pluripotent Stem Cell Derived Cardiomyocyte Engineering
    NSF/FDA Scholar In Residence: 3D Cell Adhesion Assay for Cellularized Scaffold Characterization and Enhancement
    Biohybrid Strategies for Decellularized Tissues
    海外基金